AstraZeneca and Rigel strike asthma deal worth up to $100M – FierceBiotech

AstraZeneca and Rigel strike asthma deal worth up to $100M
FierceBiotech
The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma.
AstraZeneca And Rigel Sign Worldwide License Agreement For A MarketWatch (press release)
AstraZeneca, Rigel to Develop Asthma TreatmentNASDAQ
Rigel, AstraZeneca strike potential $100M asthma drug dealBizjournals.com (blog)

all 19 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.